SCHEMBL549104

SCHEMBL549104

CC(C)c1cc(C23CC4CC(CC(C4)C2)C3)c(OCC2CO2)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
GLA P06280 1/20 0.38
SCN9A Q15858 3/20 0.35
TP53 P04637 3/20 0.33
TSHR P16473 3/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 2/20 0.33
HPGD P15428 2/20 0.33
KMT2A Q03164 2/20 0.33
HIF1A Q16665 2/20 0.33
PPARG P37231 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
IKBKB O14920 2/20 0.32
TDP1 Q9NUW8 1/20 0.31
S1PR1 P21453 1/20 0.31
PPARD Q03181 1/20 0.31
PPARA Q07869 1/20 0.31
RARA P10276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL549903 0.91 ALDH1A1 (0.38) ALDH1A1GLASCN9ATP53TSHR
SCHEMBL548846 0.88 ALDH1A1 (0.42) ALDH1A1GLATP53TSHRMEN1
SCHEMBL548767 0.85 ALDH1A1 (0.41) ALDH1A1GLATP53TSHRMEN1
SCHEMBL3767299 0.85 ALDH1A1 (0.41) ALDH1A1GLATP53TSHRMEN1
SCHEMBL548839 0.84 ALDH1A1 (0.44) ALDH1A1GLATP53TSHRMEN1
SCHEMBL549875 0.84 ALDH1A1 (0.41) ALDH1A1GLATP53TSHRMEN1
SCHEMBL548706 0.82 ALDH1A1 (0.42) ALDH1A1GLATP53TSHRMEN1
SCHEMBL549597 0.82 ALDH1A1 (0.44) ALDH1A1GLATP53TSHRMEN1
SCHEMBL549011 0.81 ALDH1A1 (0.37) ALDH1A1GLASCN9ATP53TSHR
SCHEMBL549834 0.81 ALDH1A1 (0.38) ALDH1A1GLATP53TSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110614-B2 Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative IDEMITSU KOSAN CO., LTD. (JP) 2012-02-07 US disclosed
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2010-03-04 US disclosed
EP-2090563-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE ARCN1, RTN3, CHRNA3 ALDH1A1 312/4885GLA 1474/4885SCN9A 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.